It was hypothesized that topiramate-treated patients would be better able to achieve these goals , and it was predicted that based on prior research , the effects would be moderated by a single nucleotide polymorphism ( rs2832407 ) in GRIK1 , encoding the kainate GluK1 receptor subunit .